Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease [1]

Inflammatory Bowel Diseases

Volumn 12, Issue 11, 2006, Pages 1087-1089

  Magro, F ^a,b,c   Costa, C ^c  

^a University of Porto   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c Inst of Pharmacol and Therapeutics   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; IMATINIB; INFLIXIMAB; MESALAZINE; PREDNISOLONE;

ADULT; ANAMNESIS; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COLONOSCOPY; CROHN DISEASE; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; LETTER; PRIORITY JOURNAL; RADIOGRAPHY; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; BLOOD SEDIMENTATION; CROHN DISEASE; FEMALE; HUMANS; PIPERAZINES; PLATELET COUNT; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 33750514598     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.mib.0000232468.15950.34     Document Type: Letter

References (28)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med. 2001;344:1031-1037.
2. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
3. Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-3698.
4. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
5. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
6. Okuda K, Weisberg E, Gilliland DG, et al. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97:2440-2448.
7. McGahon A, Bissonnette R, Schmitt M, et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 1994;83:1179-1187.
8. Jacquel A, Herrant M, Legros L, et al. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl positive K562 cell line and its differentiation towards the erythroid lineage. FASEB J. 2003;17:2160-2162.
9. Okada M, Adachi S, Imai T, et al. Anovel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood. 2004;103:2299-2307.
10. Dietz AB, Souan Lina, Knutson GJ, et al. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004;104:1094-1099.
11. Fuss I, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of IFN-g, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261.
12. Hollenbach E, Vieth M, Roessner A, et al. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem. 2005;280:14981-14988.
13. Levine AD. Apoptosis: implications for inflammatory bowel disease. IBD. 2000;6:191-205.
14. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol. 1999;63:1081-1090.
15. Itoh J, de La Motte C, Strong SA, et al. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut. 2001;49:35-41.
16. Sturm A, Leite AZ, Danese S, et al. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut. 2004;53:1624-1631.
17. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785.
18. Peppelenbosch MP, van Deventer SJ. T cell apoptosis and inflammatory bowel disease. Gut. 2004;53:1556-1558.
19. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145.
20. Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor-α for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
21. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet. 2002;359:1541-1549.
22. Wolf AM, Wolf D, Rumpold H, et al. The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A. 2005;102:13622-13627.
23. Aono Y, Nishioka Y, Inayama M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med. 2005;171:1279-1285.
24. Daniels Craig E, Wilkes Mark C, Edens Maryanne, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycinmediated lung fibrosis. J Clin Invest. 2004;114:1308-1316.
25. Berlin AA, Lukacs NW. Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am J Respir Crit Care Med. 2005;171:35-39.
26. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist. 2004;9:271-281.
27. Deininger MW, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637-1647.
28. Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004;100:116-121.